Arvinas, Inc. (ARVN)

10.80 -0.20 (-1.82%) USD  |  NASDAQ  |  Apr 20, 09:45
More

Arvinas SG&A Expense (Quarterly) : 23.00M for Dec. 31, 2025

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for ARVN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
Pfizer Inc. 4.162B
EyePoint, Inc. 11.38M
Apellis Pharmaceuticals, Inc. 147.10M
Elanco Animal Health, Inc. 338.00M
Gossamer Bio, Inc. 10.90M